PMID: 8591053Nov 1, 1995Paper

Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin

Current Opinion in Nephrology and Hypertension
M E CardenasJ Heitman

Abstract

The immunosuppressant cyclosporine A revolutionized treatment of graft rejection. Two newer agents, FK506 and rapamycin, show great clinical potential. These drugs suppress the immune system by forming protein-drug complexes that interact with and inhibit key components of the signal transduction pathways required for T-cell activation. The target of the cyclophilin A-cyclosporine A and FKBP12-FK506 complexes is calcineurin, a protein phosphatase required for signaling via the T-cell receptor. Cyclosporine A and FK506 nephrotoxicity may reflect renal-specific functions of calcineurin. The target of the FKBP12-rapamycin complex is TOR, a lipid and protein kinase homolog that is likely to be required for T-cell proliferation in response to interleukin-2. The identification of cyclosporine A, FK506, and rapamycin targets reveals much concerning T-cell signaling and provides the means to design novel immunosuppressants with reduced toxicity.

Citations

Apr 1, 1999·Cell Biochemistry and Biophysics·C S Hemenway, J Heitman
Feb 11, 1998·Molecular Neurobiology·B G Gold
Apr 14, 2005·Transplant International : Official Journal of the European Society for Organ Transplantation·Tudor BîrsanRandall E Morris
Jan 19, 2006·Journal of Industrial Microbiology & Biotechnology·Min He
Mar 24, 2005·Pharmaceutical Research·Alf LamprechtYoshiaki Kawashima
Mar 26, 2004·Transplantation Proceedings·B D Maes, Y F Ch Vanrenterghem
Mar 27, 2001·Transplantation Proceedings·A P Monaco
Mar 20, 1999·Transplantation Proceedings·M A Navia
Dec 16, 2003·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Mario StalderRandall E Morris
May 12, 2010·Nature Reviews. Rheumatology·José C CrispínGeorge C Tsokos
Sep 30, 2000·Kidney International·L V IvanovaD Proppe
Apr 23, 2003·Current Opinion in Rheumatology·Dean F Mayer, Sudhir S Kushwaha
Feb 5, 2002·Annual Review of Physiology·Steven C Borkan, Steven R Gullans
Aug 19, 2008·Investigative Ophthalmology & Visual Science·Matthew A CunninghamRobert B Nussenblatt
Aug 7, 2012·Journal of Translational Medicine·Anna Linda ZignegoElisa Fognani
May 17, 2006·The Journal of Investigative Dermatology·Jan P Dutz
Jul 9, 2008·Clinica Chimica Acta; International Journal of Clinical Chemistry·Shu-Ling LiangWilliam Clarke
Sep 20, 2005·Biosensors & Bioelectronics·Hisakage FunabashiEiry Kobatake
Jul 3, 2015·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Afsana JahanIndira Agarwal
Jun 13, 2015·Journal of Molecular Neuroscience : MN·Ella ZeldichCarmela R Abraham
Dec 3, 2014·Biochimica Et Biophysica Acta·Steven D Hanes
Jul 23, 1999·Renal Failure·W F Finn
Nov 5, 1997·Experimental Neurology·B G GoldD M Armistead
Dec 3, 2014·Immunology Letters·Pulak Ranjan Nath, Noah Isakov
Jun 1, 2000·Obesity Research·A BellA Sorisky
Jan 18, 2018·Biological Chemistry·Marek OrłowskiAndrzej Ożyhar
Jun 20, 2008·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Anja M GeertsIsabelle Colle
Jan 10, 2008·Molecular Pharmacology·Benayahu ElbazHannah Rahamimoff
Oct 24, 2019·Nanomedicine·Amber Nagy, Nicholas L Robbins
May 3, 2015·American Journal of Physiology. Heart and Circulatory Physiology·Elena M V de CavanaghLeón Ferder

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.